Navigation Links
PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
Date:4/25/2013

DUBLIN, Ireland, April 25, 2013 /PRNewswire/ --

Research and Markets has announced the addition of the "PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Sun Shines on Indian Generics Manufacturers

India is becoming a key market for generic medicines, and pharmaceutical companies must compete and grow their revenues there to have a shot at claiming the title of industry leader, according to a new report by research and consulting firm The authors.

Generic Manufacturers Benchmark Report states that India-based trio of Glenmark, Sun Pharmaceuticals, and Ranbaxy topped the charts in terms of year to year (YTY) revenue growth in 2012, with 71.6%, 47.6%, and 32.9% respectively. Although larger generic manufacturers - Teva, Sandoz, and Mylan - emerged as revenue leaders in 2012, with sales of US$10.4 billion, US$8.7 billion, and US$5.8 billion respectively, their performance in 2013 may vary, as other competitors, including Sun Pharmaceuticals step up efforts to grow their share of the global generics market.

Domestic players in India are currently experiencing massive growth YTY revenue as they continue to leverage many decades of reverse engineering experience. The authors believes that Indian generic manufacturers have become the go-to companies when it comes to low-cost generics, as affirmed by the entrance of pharmaceutical giants such as Gilead and Pfizer into generic manufacturing agreements with them in 2012.

Sun Pharmaceuticals holds a strong position in the Indian generics market, leading the pack in terms of operating margin and revenue growth, although the company's sales figures currently pale in comparison with larger companies. The company's domestic revenues increased by 44.9% from US$586.5m in 2011 to US$865.9m in 2012, as market shares were captured from competitors. Sun Pharmaceuticals will have to continually compete with other Indian generic manufacturers, including Ranbaxy, Dr. Reddy's and Cipla, as well as the influx of foreign generic and branded pharmaceutical companies. This rivalry, which is likely to focus on the price sensitivity of domestic consumers, could potentially decrease the company's profit margins. Nevertheless, The authors anticipates that Sun will be one to watch in 2013, as the company aims to rub shoulders with companies in the top echelon of generics manufacturing.

Mylan benefited from aggressive growth in the Indian market during 2012, as the company's generics business flourished in the country. This resulted from an increase in sales of anti-retroviral (ARV) finished dosage form (FDF) generic products, used in the treatment of HIV/AIDS. Mylan is currently one of the world's largest API manufacturers, particularly in APIs used in manufacturing generic ARV therapies for HIV/AIDS treatment. The company has total control over its supply chain, and so can effectively control cost and quality - two crucial requirements in the pharmaceuticals business.

Similarly, Teva and Sandoz are stepping up efforts to grow their revenues outside established markets. Sandoz, in particular, needs to gain ground in emerging markets, as 80% of its generic pharmaceutical sales currently come from the US and Europe, leaving the company exposed to the current pricing pressures and budget deficits in these markets.

Key Topics:

1 Tables & Figures

2 Introduction

3 GlobalData Benchmark Rankings

4 Financial Management

5 Expense Management

6 Capital Management

7 Key Players

  • Sun Pharmaceuticals: The Benchmark Leader
  • Sandoz
  • Pharmstandard
  • Teva Pharmaceuticals
  • Actavis
  • Mylan
  • Ranbaxy
  • Dr. Reddy's
  • Covidien
  • Hospira

8 Outlook

For more information visit PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

Research and Markets
Laura Wood , Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
2. Watsons Generic Yaz(R) Receives FDA Approval
3. Watsons Generic BONIVA® 150mg Receives FDA Approval
4. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
5. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
6. Lupin Receives FDA Approval for Generic LYRICA(R)
7. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
8. Generic Pharma Partnering Yearbook 2013 - Access to the Partnering Deals and Agreements Globally
9. Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
10. iLab Solutions Conducts Its Third Annual Core Facility Benchmarking Study
11. ISPE Conference to Benchmark and Advance Quality by Design in the Biopharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... DALLAS , Dec. 6, 2016 ... criminal justice technology solutions for public safety, investigation, ... (PEP) jointly announced today a five (5) year ... exclusive agreement to expand the rehabilitation and reentry ... PEP History Established in 2004, the Prison ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):